作者
KA Ahmed, YA Abuodeh, MI Echevarria, JA Arrington, DG Stallworth, C Hogue, AO Naghavi, S Kim, Y Kim, BG Patel, S Sarangkasiri, PAS Johnstone, S Sahebjam, NI Khushalani, PA Forsyth, LB Harrison, M Yu, AB Etame, JJ Caudell
发表日期
2016/12/1
期刊
Annals of Oncology
卷号
27
期号
12
页码范围
2288-2294
出版商
Elsevier
简介
Novel targeted and immunotherapeutic agents have revolutionized systemic melanoma management. We note differing rates of distant brain control as well as overall survival following systemic treatment and stereotactic radiosurgery (SRS) in melanoma brain metastases management. These data support further research to determine the potential synergistic effect between these agents with SRS.
Background
The effect of immunologic and targeted agents on intracranial response rates in patients with melanoma brain metastases (MBMs) is not yet clearly understood. This report analyzes outcomes of intact MBMs treated with single-session stereotactic radiosurgery (SRS) and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors(i), BRAFi, or conventional chemotherapy.
Patients and methods
Patients were included if MBMs were treated with single-session SRS within 3 months of receiving systemic therapy …
学术搜索中的文章
KA Ahmed, YA Abuodeh, MI Echevarria, JA Arrington… - Annals of Oncology, 2016